This report provides information on the therapeutic development for Proliferative Diabetic Retinopathy (PDR), complete with latest updates, and special features on late-stage and discontinued projects.
What does PDR stand for?
PDR stands for Proliferative Diabetic Retinopathy
This definition appears very frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of PDR
We have 287 other meanings of PDR in our Acronym Attic
- Professional Development Reimbursement (various organizations)
- Professional Development Ribbon
- Program Data Requirement
- Program Definition Review
- Program Design Review
- Program Deviation Report
- Program Director's Review (various organizations)
- Program Document Review (Army Training)
- Programmable Digital Radio
- Project Definition Report
- Prospective Drug Review
- Proved Developed Reserve (oil exploration)
- Provider Dispute Resolution (various organizations)
- Public Data Release (US EPA)
- Public Disclosure Request (proprietary information)
- Public Document Room
- Pulse Doppler Radar
- Pulse Dose Rate (radiation therapy)
- Purchase of Development Rights
- Pygmy Dipole Resonance
Samples in periodicals archive:
In cases of severe proliferative diabetic retinopathy, new blood vessels may grow on the surface of the iris, causing neovascular glaucoma, a particularly severe form of glaucoma.
2 million have diabetic retinopathy, and in 675,000 of them, it progresses to its most severe form, proliferative diabetic retinopathy in which abnormal -- and leaky blood vessels intrude into the eyeball's clear vitreous gel, causing retinal traction and bleeding that results in decreased sight.
Regardless of insulin choice, rapid tightening of glycemic control is among the predictors of proliferative diabetic retinopathy during pregnancy, along with the duration of diabetes, Hb[A.
Proliferative diabetic retinopathy occurs when new blood vessels form on the optic disc or another component of the retina.
CHICAGO -- Intravitreal pegaptanib appeared to induce regression of proliferative diabetic retinopathy in a small pilot study presented at the annual scientific sessions of the American Diabetes Association.
Scott MacGregor 317-651-1494 (office) 317-440-4699 (mobile) RUBOXISTAURIN REDUCED VISION LOSS IN PATIENTS WITH MODERATE TO SEVERE NON- PROLIFERATIVE DIABETIC RETINOPATHY IN A NEW STUDY - Once Daily, Oral Investigational Therapy Reduced Sustained Moderate Vision Loss Over Three-Year Period - INDIANAPOLIS, IN - November 13, 2006 - Eli Lilly and Company (NYSE: LLY) today announced results from a three-year phase 3 clinical trial in which ruboxistaurin mesylate (proposed brand name ArxxantTM, pronounced ark-ZONT) reduced the risk of sustained moderate vision loss by 40 percent when compared to placebo in patients with moderate to severe non-proliferative diabetic retinopathy (DR).
A modeled economic analysis of a digital tele-ophthalmology system as used by three federal health care agencies for detecting proliferative diabetic retinopathy.